Internal Medicine, Medical Oncology · Saint Louis, MO
NPI
1316965320
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
4500 Forest Park Ave, Div Im Bone Marrow Transplant, 5th, 6th, 8th Fl
Saint Louis, MO, 63108
Phone (314) 454-8304
Groups this clinician bills Medicare through
Medicare paid, 2024
$87K
3,594 services
Medicare patients, 2024
158
Average age 74
Drug cost, 2024
$9.9M
1,944 prescriptions
Company payments, 2025
$2,217
From 7 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Camille N Abboud was code 99214 (office e&m - established), 262 times for 129 patients. In total Camille N Abboud billed 3,594 services in 38 codes, and Medicare paid $87K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-04-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 262 | 129 | $92.33 | $24K |
| 36415 Venipuncture Blood Collection | Office | 69 | 33 | $8.65 | $597 |
| 99215 Office E&M - Established | Office | 19 | 19 | $135.13 | $2,568 |
By year: 2022 $826K for 47,843 services; 2023 $1.0M for 46,918 services; 2024 $87K for 3,594 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 69 | 33 | $8.65 | $597 |
Medicare prescription drug claims, 2024
In 2024, the drug Camille N Abboud prescribed most often to Medicare patients was Brukinsa (Zanubrutinib), with 196 prescriptions and refills. In total Camille N Abboud wrote 1,944 Medicare prescriptions that cost $9.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Brukinsa Zanubrutinib | 196 | 196 | 26 | $2.8M |
| Acyclovir Generic | 180 | 254 | 47 | $3,097 |
| Revlimid Lenalidomide | 82 | 82 | Under 11 | $1.5M |
| Valacyclovir Valacyclovir Hcl | 75 | 109 | 15 | $1,663 |
| Allopurinol Generic | 63 | 107 | 23 | $366 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 59 | 97 | 15 | $340 |
| Venclexta Venetoclax | 57 | 57 | 20 | $364K |
| Ursodiol Generic | 55 | 79 | 12 | $5,296 |
| Jakafi Ruxolitinib Phosphate | 49 | 53 | Under 11 | $851K |
| Imatinib Mesylate Generic | 49 | 61 | Under 11 | $158K |
| Calquence Acalabrutinib Maleate | 45 | 45 | Under 11 | $685K |
| Pantoprazole Sodium Generic | 42 | 65 | 11 | $308 |
| Fluconazole Generic | 41 | 43 | Under 11 | $4,017 |
| Prochlorperazine Maleate Generic | 40 | 40 | 25 | $922 |
| Oxycodone Hcl Generic | 36 | 36 | Under 11 | $240 |
Brand drugs: - claims; generic drugs: 1,225 claims; opioid claims: 54.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Camille N Abboud $2,217 ($1,213 in general payments such as food, travel and fees and $1,004 for research) from 7 companies. The largest payer was Novartis Pharmaceuticals Corporation with $1,144.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.